APA (7th ed.) Citation

Tu, Y., Lagraauw, H. M., Method, M., Wang, Y., Hanze, E., Li, L., . . . Westin, E. H. (2025). Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen. British Journal of Clinical Pharmacology, 91(1), 220. https://doi.org/10.1111/bcp.16250

Chicago Style (17th ed.) Citation

Tu, Ya‐Ping, H. Maxime Lagraauw, Michael Method, Yuemei Wang, Eva Hanze, Lingling Li, Timothy Parrott, Callum M. Sloss, and Eric H. Westin. "Exposure–response Relationships of Mirvetuximab Soravtansine in Patients with Folate Receptor‐α‐positive Ovarian Cancer: Justification of Therapeutic Dose Regimen." British Journal of Clinical Pharmacology 91, no. 1 (2025): 220. https://doi.org/10.1111/bcp.16250.

MLA (9th ed.) Citation

Tu, Ya‐Ping, et al. "Exposure–response Relationships of Mirvetuximab Soravtansine in Patients with Folate Receptor‐α‐positive Ovarian Cancer: Justification of Therapeutic Dose Regimen." British Journal of Clinical Pharmacology, vol. 91, no. 1, 2025, p. 220, https://doi.org/10.1111/bcp.16250.